Evaluation of the efficacy and safety of DNN.22.17.036 versus 10573048700 in the treatment of male pattern hair loss.

Inclusion Criteria:

• Ability to understand and consent to participate in this clinical research, expressed by signing the Informed Consent Form (ICF)
• Male participants age 25 or older and 60 age or younger
• Participants who have an intact scalp in the area of product analysis
• Participants with androgenetic alopecia (AGA) with AGA Norwood-Hamilton Scale > II
• Participants with at least 20% telogen effluvium of evaluated by Tricholab

Exclusion Criteria:

• Participants who have used immunosuppressants in the 3 months prior to signing the ICF
• Participants with other causes of hair loss or scalp dermatoses
• Participants who have received hair loss treatment in the last 6 months
• Participants with uncontrolled medical conditions, kidney and liver disease
• Participants with a history of hair transplantation, malignancy, hematologic disorders, thyroid dysfunction, malnutrition, and other dermatologic disorders that contribute to hair loss